» Articles » PMID: 16076871

Direct Recruitment of CRK and GRB2 to VEGFR-3 Induces Proliferation, Migration, and Survival of Endothelial Cells Through the Activation of ERK, AKT, and JNK Pathways

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2005 Aug 4
PMID 16076871
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular endothelial growth factor receptor-3 (VEGFR-3) plays a key role for the remodeling of the primary capillary plexus in the embryo and contributes to angiogenesis and lymphangiogenesis in the adult. However, VEGFR-3 signal transduction pathways remain to be elucidated. Here we investigated VEGFR-3 signaling in primary human umbilical vein endothelial cells (HUVECs) by the systematic mutation of the tyrosine residues potentially involved in VEGFR-3 signaling and identified the tyrosines critical for its function. Y1068 was shown to be essential for the kinase activity of the receptor. Y1063 signals the receptor-mediated survival by recruiting CRKI/II to the activated receptor, inducing a signaling cascade that, via mitogen-activated protein kinase kinase-4 (MKK4), activates c-Jun N-terminal kinase-1/2 (JNK1/2). Inhibition of JNK1/2 function either by specific peptide inhibitor JNKI1 or by RNA interference (RNAi) demonstrated that activation of JNK1/2 is required for a VEGFR-3-dependent prosurvival signaling. Y1230/Y1231 contributes, together with Y1337, to proliferation, migration, and survival of endothelial cells. Phospho-Y1230/Y1231 directly recruits growth factor receptor-bonus protein (GRB2) to the receptor, inducing the activation of both AKT and extracellular signal-related kinase 1/2 (ERK1/2) signaling. Finally, we observed that Y1063 and Y1230/Y1231 signaling converge to induce c-JUN expression, and RNAi experiments demonstrated that c-JUN is required for growth factor-induced prosurvival signaling in primary endothelial cells.

Citing Articles

Regulation of VEGFR3 signaling in lymphatic endothelial cells.

Kuonqui K, Campbell A, Pollack B, Shin J, Sarker A, Brown S Front Cell Dev Biol. 2025; 13:1527971.

PMID: 40046235 PMC: 11880633. DOI: 10.3389/fcell.2025.1527971.


Lymphatic transport in anti-tumor immunity and metastasis.

Sun M, Angelillo J, Hugues S J Exp Med. 2025; 222(3).

PMID: 39969537 PMC: 11837853. DOI: 10.1084/jem.20231954.


Emerging Nanomedicine Approaches in Targeted Lung Cancer Treatment.

Alexandru I, Davidescu L, Motofelea A, Ciocarlie T, Motofelea N, Costachescu D Int J Mol Sci. 2024; 25(20).

PMID: 39457017 PMC: 11508987. DOI: 10.3390/ijms252011235.


The role of vascular and lymphatic networks in bone and joint homeostasis and pathology.

Huang J, Liao C, Yang J, Zhang L Front Endocrinol (Lausanne). 2024; 15:1465816.

PMID: 39324127 PMC: 11422228. DOI: 10.3389/fendo.2024.1465816.


Targeting lymphatic function in cardiovascular-kidney-metabolic syndrome: preclinical methods to analyze lymphatic function and therapeutic opportunities.

Fowler J, Song L, Tam K, Flach R Front Cardiovasc Med. 2024; 11:1412857.

PMID: 38915742 PMC: 11194411. DOI: 10.3389/fcvm.2024.1412857.